Tolerx
closedNovel therapies that modulate T-cell activities to treat patients with autoimmune diseases, diabetes and cancer.
Launch date
Employees
Market cap
-
Enterprise valuation
$6—9m (Dealroom.co estimates Dec 2010.)
Cambridge Massachusetts (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
$17.0m | Series B | ||
$35.0m | Series C | ||
$31.0m | Series D | ||
$61.0m | Series D | ||
| N/A | $1.5m | Early VC | |
| Total Funding | $145m | ||
Related Content
Recent News about Tolerx
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.